ALFA Finder| Revenue growth | 12% Q-o-Q revenue growth delivered in Q4 FY26. |
|---|---|
| Margins | Base business at 54% gross margin; overall EBITDA margin 16%. |
| Order book | Base business order book remains strong and a primary driver. |
| Demand visibility | Healthy order book in base business; 30% spare capacity available. |
| Management confidence | High in base business; cautious on Ibuprofen turnaround. |
Growth
Revenue grew 12% Q-o-Q; EBITDA grew 65% Q-o-Q to INR 61cr; 16% overall EBITDA margin.
Outlook
Evaluating strategic options for Ibuprofen; aiming to be debt-free by FY29; 4-5 DMF filings planned annually.
Risks
Persistent headwinds in Ibuprofen (negative EBITDA); Middle East crisis impact; reliance on third-party IBB/IBAP sourcing.
Earnings Call filed with BSE, NSE: SOLARA. Summary written with AI assistance from the document.
Solara Active Pharma Sciences Ltd: key numbers
- Share price
- ₹668.45
- Market cap
- ₹3,220 Cr
- Revenue (annual)
- ₹1,369 Cr
- Net profit (annual)
- ₹-7.41 Cr
- P/E (TTM)
- 87.2×Sector 43.8×
- Promoter holding
- 41.93%+0.00% QoQ
- FII holding
- 10.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Solara Active Pharma Sciences Ltd
All →Solara Active Pharma Sciences Other Announcement
Solara Active Pharma Sciences Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026. This disclosure details equity ownership across various investor categories.
Solara Active Pharma Sciences Earnings Call Transcript: Key Takeaways
Solara delivered its best profitability in five years despite ongoing Ibuprofen pricing and raw material challenges.
Solara Active Pharma Sciences Investor Presentation: Key Takeaways
Solara's Q2 FY27 delivered record EBITDA and PAT in five years, driven by 33% revenue growth. Base business strength offset Ibuprofen headwinds, which is now nearing breakeven.
Solara Active Pharma Sciences Employee Stock Options
Solara Active Pharma Sciences Limited allotted 8,300 equity shares under its 2018 ESOP plan. The exercise of these options realized Rs. 0.31 Crore for the company.
- Value
- ₹0.31 Cr
Solara Active Pharma Sciences Q2 FY27 Results: Turns Profitable, Net Profit ₹28.5 Cr
Solara Active Pharma Sciences Ltd reported revenue from operations of ₹417.3 Cr (+33.1% YoY) and net profit of ₹28.5 Cr for Q2 FY27.
- Key figure
- Net profit ₹28.5 Cr
Solara Active Pharma Sciences Other Announcement
Solara Active Pharma received an ESG rating of 63 ('Strong' category) from Crisil ESG Ratings for the fiscal year 2026, an upgrade from the prior year.